The goal of the Parker Institute for Cancer Immunotherapy is to accelerate the development of cutting-edge immune therapies capable of turning cancer into a curable disease by ensuring the collaboration of the field’s top researchers and quickly converting their findings into patient treatments.
Officials are Takeda Pharmaceutical Company Limited recently released the results from its randomized, international, placebo-controlled, double-blind, phase-three trial for Ninlaro, the first oral proteasome inhibitor.
Leaders at the U.S. Food and Drug Administration (FDA) recently granted approval of Xalkori to treat patients who have advanced (metastatic) non-small cell lung cancer (NSCLC) and tumors with an ROS-1 gene alteration.
The ALS Association recently published a new report, called 'Medicines in Development for Rare Diseases,' to show that U.S. biopharmaceutical research companies are working hard to create new medicines for rare diseases.
The FDA recently expanded the label for Imbruvica (ibrutinib) to include data that show the overall survival increases for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Leaders at the American Heart Association recently reported that peripheral artery disease (PAD) patients who take statins, which are meant to lower cholesterol, may have a lower risk of death and amputation compared to patients without statins.
Recent preliminary research from the American Heart Association suggests that restoring leg blood flow for patients who have peripheral artery disease (PAD) may inhibit the leg muscle scarring common with the disease.
New research from the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), suggests that cancer treatments may be useful for treating uncontrollable immune responses to infections like sepsis.
Research teams have conducted a rapid-acting, non-addicting agent for a mouse study that has shown a chemical byproduct (metabolite) that breaks down ketamine could be the key to ketamine’s fast-acting antidepressant action.
The National Organization for Rare Disorders (NORD) recently released data about 20 rare disease patient groups that are part of the organizations’ natural history studies, a branch of its cooperative agreement with the FDA.
The Autism Speaks MSSNG program recently announced that it has collected its biggest upload and release of the program’s whole genome sequences, all gathered from people who have autism and their family members.